Kidney Disease Clinical Trials

Showing 3261-3280 of 3,902 trials

Phase I Study of Alpha-Melanocyte Stimulating Hormone in Patients With Acute Renal Failure

NCT00004496

OBJECTIVES: I. Determine the maximum tolerated dose and safety of alpha-melanocyte stimulating hormone (alpha-MSH) in patients with acute renal failure. II. Determine the safety and pharmacokinetics of alpha-MSH in patients at high risk of acute renal failure after renal transplantation. III. Determine the safety and pharmacokinetics of alpha-MSH in patients with established ischemic acute renal failure. IV. Determine the effect of alpha-MSH on interleukin-10 pharmacokinetics.

Acute Renal Failure

University of Texas45 participantsStarted Feb 1999

Dallas, Texas, United States • Dallas, Texas, United States

TERMINATEDPhase 3

A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis

NCT00833768

Approximately 207 hyperphosphatemic CKD patients not on dialysis will be entered into this study at approximately 50 sites within approximately 9 European countries. The purpose of this study is to determine if sevelamer carbonate tablets dosed three times a day (TID) is a safe and effective treatment for the control of serum phosphorous levels in hyperphosphatemic CKD patients not on dialysis. Total length of participation is approximately 24 weeks.

Chronic Kidney DiseaseHyperphosphatemia

Genzyme, a Sanofi Company5 participantsStarted Jan 2009

Graz, Austria • Innsbruck, Austria • Linz, Austria +33 more locations

Phase I Study of Alpha-Melanocyte Stimulating Hormone in Patients With Acute Renal Failure

A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis

Related Searches

Post Authorisation Safety Study of Renvela® in Chronic Kidney Disease Patients Not on Dialysis With Hyperphosphataemia

An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis

Efficacy Study of Different Analgesic Options in Kidney Stone Pain Management

Use of Ointments in Prevention of Catheter Related Infections in PD

Dialysis Clinical Outcomes Revisited (DCOR) Trial

An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.

External Ionizing Radiation to Prevent Restenosis on Haemodialysis Vascular Access

Effect of Reducing Phosphorus Absorption on Cardiac Biomarkers in Hemodialysis Patients

Sympathetic Nerve Activity in Renal Failure

Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate

Optimal Treatment for Kidney Disease in HIV Infected Adults

Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing

Value of Various Chemokines in the Detection and Follow up of RCC

Single Pass Albumin Dialysis in Patients With Cirrhosis

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With ERSD Receiving Maintenance Hemodialysis

Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium

Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP